News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
182,484 Results
Type
Article (17495)
Company Profile (131)
Press Release (164858)
Section
Business (58598)
Career Advice (933)
Deals (9609)
Drug Delivery (34)
Drug Development (23663)
Employer Resources (70)
FDA (2338)
Job Trends (4241)
News (93082)
Policy (5809)
Tag
Academia (497)
Alliances (16320)
Alzheimer's disease (399)
Antibody-drug conjugate (ADC) (56)
Approvals (2305)
Artificial intelligence (65)
Bankruptcy (78)
Best Places to Work (2899)
Biotechnology (121)
Breast cancer (66)
Cancer (559)
Career advice (752)
CAR-T (65)
Cell therapy (193)
Clinical research (18470)
Collaboration (270)
Compensation (60)
COVID-19 (740)
C-suite (77)
Data (509)
Diabetes (45)
Diagnostics (1048)
Drug discovery (46)
Earnings (15799)
Employer resources (68)
Events (31095)
Executive appointments (223)
FDA (2515)
Funding (222)
Gene therapy (120)
GLP-1 (235)
Government (611)
Healthcare (2462)
Infectious disease (782)
Inflammatory bowel disease (58)
Interviews (136)
IPO (4310)
Job creations (1474)
Job search strategy (699)
Layoffs (139)
Legal (1179)
Lung cancer (62)
Lymphoma (45)
Manufacturing (107)
Medical device (706)
Medtech (707)
Mergers & acquisitions (5402)
Metabolic disorders (164)
Neuroscience (547)
NextGen Class of 2024 (1455)
Non-profit (460)
Northern California (641)
Obesity (89)
Opinion (166)
Patents (42)
People (21924)
Phase I (7187)
Phase II (8804)
Phase III (4970)
Pipeline (228)
Postmarket research (309)
Preclinical (2953)
Press Release (61)
Radiopharmaceuticals (79)
Rare diseases (120)
Real estate (2434)
Regulatory (4397)
Research institute (535)
Resumes & cover letters (152)
Series A (49)
Southern California (607)
Startups (1789)
United States (5319)
Vaccines (186)
Weight loss (70)
Date
Today (12)
Last 7 days (263)
Last 30 days (909)
Last 365 days (12839)
2024 (12789)
2023 (13469)
2022 (16287)
2021 (17265)
2020 (13459)
2019 (9643)
2018 (7672)
2017 (9083)
2016 (8214)
2015 (9527)
2014 (9777)
2013 (9492)
2012 (6097)
2011 (6480)
2010 (5868)
Location
Africa (323)
Asia (13470)
Australia (2673)
California (1486)
Canada (529)
China (127)
Connecticut (60)
Europe (29968)
Florida (149)
Illinois (105)
Indiana (77)
Maryland (219)
Massachusetts (1159)
Michigan (63)
Minnesota (100)
New Jersey (412)
New York (358)
North Carolina (278)
Northern California (641)
Ohio (41)
Pennsylvania (322)
South America (401)
Southern California (607)
Texas (156)
Washington State (262)
182,484 Results for "psc biotech".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced interim results from two Phase 2b studies evaluating volixibat, an oral ileal bile acid transporter (IBAT) inhibitor in patients with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).
June 17, 2024
·
9 min read
Funding
Navigating a Biotech Exit in a Rebounding Market
With climbing biotech M&A and IPO activity following the post-pandemic slump, experts offer insights on maximizing value and otherwise capitalizing on exit opportunities.
November 6, 2024
·
8 min read
·
Ana Mulero
Business
Newly Private NGM Bio Raises $122M for Registrational PSC Study
After completing a buyout transaction with The Column Group to remove it from the stock exchange, NGM Bio has raised a $122M Series A to fund a registrational study for a rare liver disease drug and a Phase II trial in hyperemesis gravidarum.
July 17, 2024
·
1 min read
·
Kate Goodwin
Press Releases
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024
October 17, 2024
·
6 min read
Earnings
Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more
BioSpace
takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.
November 12, 2024
·
9 min read
·
Annalee Armstrong
Deals
5 Radiopharma Biotechs to Watch for Potential Buyouts
Big Pharma can’t seem to get enough radiopharmaceutical biotechs. With Lilly, Sanofi and BMS chasing Novartis into the complex space, all eyes are on these specialty biotechs.
October 9, 2024
·
5 min read
·
Annalee Armstrong
Job trends
Cell Therapy Biotechs Hunt for Autoimmune Expertise in Pivot From Oncology
In a tough fundraising space, cell therapy biotechs pursuing autoimmune indications review staffing to ensure the right expertise is in place to tackle the new disease area.
November 6, 2024
·
6 min read
·
Annalee Armstrong
Career Advice
Breaking Into Biotech: What You Must Know to Enter Industry
Candidates looking to enter biotech should focus on cultivating key skills, thoughtfully crafting their resumes and putting their best, most authentic foot forward in interviews. An internship, co-op or fellowship won’t hurt, either.
October 31, 2024
·
6 min read
·
Angela Gabriel
Obesity
Lilly’s Sprawling Obesity Clinical Program Underscores Challenges for Biotechs
Eli Lilly CEO David Ricks is confident his company and peer Novo Nordisk are years ahead in the weight loss space, as biotechs press on with compelling data.
October 9, 2024
·
3 min read
·
Annalee Armstrong
Deals
After Fed Rate Cut, Biotech Stocks Face ‘Anticlimactic’ Reality
The drop in interest rate is slightly bigger than anticipated and good news for the biotech industry, but little will change in the near term.
September 19, 2024
·
3 min read
·
Annalee Armstrong
1 of 18,249
Next
